Dennis Kim

41PUBLICATIONS
57CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCarbon capture engineering (excl. sequestration)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Jun 29, 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

|Apr 23, 2026
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.

|Mar 30, 2026
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Maria Agustina Perusini, Katia Pagnano, Carolina Pavlovsky

|Jan 15, 2026
A small step yet one giant leap for cGVHD biomarkers.

Igor Novitzky-Basso, Dennis Dong Hwan Kim

|Oct 24, 2025
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.

Sergio Rodriguez-Rodriguez, Nihar Desai, Christopher Lemieux

|Sep 18, 2025
Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65 years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis.

Ruah Alyamany, Ahmed Alnughmush, Mats Remberger

Pageof 7

Frequent Collaborators

22 joint publications

Fotios V Michelis

18 joint publications

Arjun Law

16 joint publications

Rajat Kumar

15 joint publications

Ivan Pasic